CA
VRCA icon

CoreCap Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

CoreCap Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$550 Buy
+20
New +$534 ﹤0.01% 2151
2022
Q3 		– Sell
-20
Closed – – 2066
2022
Q2 		$0 Buy
+20
New +$1K ﹤0.01% 2288
2022
Q1 		– Sell
-20
Closed -$2K – 2065
2021
Q4 		$2K Buy
+20
New +$2.27K ﹤0.01% 2005

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
CI
Conning Inc Hartford, Connecticut $3.34B AUM 25.19% 1-Year Est. Return

CoreCap Advisors's VRCA Position: Q4 2022 in Review

CoreCap Advisors opened a new position in Verrica Pharmaceuticals (VRCA) in Q4 2022: 20 shares worth $550. The stake represents ﹤0.01% of the portfolio and ranks #2151 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in VRCA as recently as Q2 2022.

CoreCap Advisors first reported a position in VRCA in Q4 2021 and has held it in 3 quarters since. The position peaked at $2K in Q4 2021. 50 funds tracked by Wall St. Rank hold VRCA as of Q4 2022.

  • CoreCap Advisors held 20 shares of Verrica Pharmaceuticals worth $550 as of Q4 2022.
  • Verrica Pharmaceuticals was a new CoreCap Advisors position in Q4 2022.
  • Verrica Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q4 2022, its #2151 holding.
  • CoreCap Advisors first reported a position in Verrica Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
  • CoreCap Advisors's Verrica Pharmaceuticals position peaked at $2K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.